Designer bugs as cancer drugs?

Area of Science:

• Microbiology
• Immunology
• Oncology

Background:

• The skin harbors a complex microbial community (skin microbiota) that plays a crucial role in maintaining skin health and immunity.
• Dysbiosis of the skin microbiota has been linked to various skin conditions and systemic diseases.
• Emerging evidence suggests the skin microbiota can influence systemic immune responses, including antitumor immunity.

Purpose of the Study:

• To investigate the potential of engineering the skin microbiota to elicit an antitumor immune response.
• To determine if specific modifications to the skin microbiota can enhance the activity of T cells against tumors.

Main Methods:

• Utilized genetically modified bacteria to colonize the skin.
• Employed mouse models of cancer to assess the impact of engineered skin microbiota on tumor growth.
• Analyzed immune cell populations, particularly T cells, in the tumor microenvironment and draining lymph nodes.

Main Results:

• Engineered skin microbiota successfully colonized the skin and modulated the local immune environment.
• Treatment with engineered skin microbiota led to a significant reduction in tumor growth in mouse models.
• Enhanced infiltration and activation of antitumor T cells were observed in the tumor microenvironment.

Conclusions:

• Engineering the skin microbiota represents a viable strategy for inducing antitumor T cell responses.
• Modulating the skin microbiome holds promise as a novel therapeutic approach for cancer treatment.
• Further research is warranted to translate these findings into clinical applications for cancer immunotherapy.